JP2022540198A5 - - Google Patents
Info
- Publication number
- JP2022540198A5 JP2022540198A5 JP2022501148A JP2022501148A JP2022540198A5 JP 2022540198 A5 JP2022540198 A5 JP 2022540198A5 JP 2022501148 A JP2022501148 A JP 2022501148A JP 2022501148 A JP2022501148 A JP 2022501148A JP 2022540198 A5 JP2022540198 A5 JP 2022540198A5
- Authority
- JP
- Japan
- Prior art keywords
- structural
- combination
- functional analog
- ischemia
- reperfusion injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20190100288 | 2019-07-09 | ||
| GR20190100288 | 2019-07-09 | ||
| PCT/EP2020/069343 WO2021005147A1 (en) | 2019-07-09 | 2020-07-09 | Combination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540198A JP2022540198A (ja) | 2022-09-14 |
| JP2022540198A5 true JP2022540198A5 (https=) | 2023-07-18 |
| JP7758655B2 JP7758655B2 (ja) | 2025-10-22 |
Family
ID=71614868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501148A Active JP7758655B2 (ja) | 2019-07-09 | 2020-07-09 | 組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220265776A1 (https=) |
| EP (1) | EP3996717A1 (https=) |
| JP (1) | JP7758655B2 (https=) |
| CN (2) | CN114423461B (https=) |
| WO (1) | WO2021005147A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240366729A1 (en) | 2021-08-27 | 2024-11-07 | Genesis Pharma Sa | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea |
| WO2023146838A1 (en) * | 2022-01-25 | 2023-08-03 | Enterin, Inc. | Methods for treating or preventing neurodegenerative disease using a combination of aminosterols and an insulin compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US9016221B2 (en) * | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| EP1802313B1 (en) | 2004-09-18 | 2010-11-03 | University of Maryland, Baltimore | Therapeutic agents trageting the ncca-atp channel and methods of use thereof |
| WO2008046014A1 (en) * | 2006-10-12 | 2008-04-17 | Remedy Pharmaceuticals, Inc. | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors |
| WO2008156654A2 (en) * | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| DE102009001283A1 (de) * | 2009-03-02 | 2010-09-09 | Ernst-Moritz-Arndt-Universität Greifswald | Mineralcorticoidrezeptorantagonisten zur Verminderung eines Myokardinfarktes bei einer Reperfusion |
| KR20240090632A (ko) * | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) * | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| US20140256626A1 (en) | 2011-10-18 | 2014-09-11 | Prolynx Llc | Peg conjugates of exenatide |
| US20130196906A1 (en) * | 2012-01-31 | 2013-08-01 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| US20130196946A1 (en) * | 2012-01-31 | 2013-08-01 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| ES2791301T3 (es) * | 2015-11-06 | 2020-11-03 | Genesis Pharma Sa | Combinación de canrenoato y exenatida |
| US20240366729A1 (en) * | 2021-08-27 | 2024-11-07 | Genesis Pharma Sa | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea |
-
2020
- 2020-07-09 US US17/624,690 patent/US20220265776A1/en active Pending
- 2020-07-09 CN CN202080057768.6A patent/CN114423461B/zh active Active
- 2020-07-09 EP EP20740268.6A patent/EP3996717A1/en active Pending
- 2020-07-09 JP JP2022501148A patent/JP7758655B2/ja active Active
- 2020-07-09 CN CN202411644642.5A patent/CN120267840A/zh active Pending
- 2020-07-09 WO PCT/EP2020/069343 patent/WO2021005147A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4391087B2 (ja) | 癌の処置のための薬学的組み合わせ | |
| JP2005501110A5 (https=) | ||
| JP2008530124A (ja) | フラビウイルス感染症を処置または予防するための組成物および方法 | |
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| MX2008016254A (es) | Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia. | |
| KR20120107995A (ko) | 심방세동의 치료 방법 | |
| JP2022540198A5 (https=) | ||
| JP2012502047A (ja) | 心房細動を治療する方法 | |
| CA2150780A1 (en) | Inhibitor of vascular permeability enhancer | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 | |
| JP3070930B2 (ja) | 脳血管性疾患治療剤および抗炎症剤 | |
| AU711176B2 (en) | Combination therapy for HIV infection using the HIV protease inhibitor indinavir and the reverse transcriptase inhibitor 3TC, optionally together with AZT, DDI or DDC | |
| CA2450915C (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| KR20110026421A (ko) | 심장율동전환의 예방을 위한 드로네다론 | |
| HU206826B (en) | Pharmaceutical compositions containing 7-oxa-bicyclo-heptane-prostaglandine analogue for treating or preventing migrain | |
| JP2024534156A5 (https=) | ||
| JP2008520681A5 (https=) | ||
| JP2022540198A (ja) | 組合せ | |
| CN109966290A (zh) | Cid1067700在制备预防和/或治疗脑血管疾病的药物中的应用及其药物组合物 | |
| JP2957618B2 (ja) | アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物 | |
| RU2432948C2 (ru) | Применение активаторов растворимой гуанилатциклазы для лечения нарушений кровоснабжения | |
| JP2009531367A5 (https=) | ||
| KR20050054921A (ko) | 저알부민 상태의 개선제 | |
| JP2023554354A5 (https=) | ||
| EP4142714A1 (en) | N-acetylserotonin derivatives as trkb activators and uses thereof |